Fig. 1.
![Fig. 1. (A) Surface expression of HLA class I, HLA class II, and CD80, CD86, and CD34 molecules on untreated AML cells and AML cells cultured with GM-CSF, IL-4, and TNF-. I, No MoAb; II, anti-CD80; III, anti-CD86; IV, anti-DR; V, anticlass I; VI, CD34. Cells were labeled with fluorescein-conjugated MoAbs and analyzed on a FACS. (B) Proliferative responses of hsp65 (aa418-427)-specific T-cell clone R2F10 and HLA-DR13-specific alloreactive clone against untreated or cytokine treated (72 hours) AML cells. Antigens (hsp65, 5μg/mL; and hsp65 peptide 418-427, 1 μg/mL) were added in the assay. The results are expressed as stimulation index (cpm in the presence of stimulator [APC]-cpm in the absence of stimulator/cpm in the absence of the stimulator).](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/92/5/10.1182_blood.v92.5.1677/4/blod41714001x.jpeg?Expires=1723248893&Signature=hjAQ9wlosEJbNF-o36SwtyYYKpIS1MghE2rCRlQifKNA0iABvh~kGIYhXEqtqqhS0zsyPXjft0Iq3z2RdCaq4In0ppAEhQ5a2c19fSlchr31Trhg6SKA9fS0YdXM4EEzxnhkaneNBoJK5jCaycjmHGuK9vxyaHxmJ1kIwJRYGAUyyUyVEbHikfljeb1wXQsC6gy1LqP7n0FMWdPueeO3~BweKtU0WpKDtc7dP35rzt0h4cYN7IlFwc-q8JHRRPXvag0L3x2Tlbw5pNhJ1z4dFUJV6Qib2WP-fr0DI~Wx6lTVZwSOHHzjunDIAyJkJM7nsJE6sl8wBaB4aNXylRiDuA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
(A) Surface expression of HLA class I, HLA class II, and CD80, CD86, and CD34 molecules on untreated AML cells and AML cells cultured with GM-CSF, IL-4, and TNF-. I, No MoAb; II, anti-CD80; III, anti-CD86; IV, anti-DR; V, anticlass I; VI, CD34. Cells were labeled with fluorescein-conjugated MoAbs and analyzed on a FACS. (B) Proliferative responses of hsp65 (aa418-427)-specific T-cell clone R2F10 and HLA-DR13-specific alloreactive clone against untreated or cytokine treated (72 hours) AML cells. Antigens (hsp65, 5μg/mL; and hsp65 peptide 418-427, 1 μg/mL) were added in the assay. The results are expressed as stimulation index (cpm in the presence of stimulator [APC]-cpm in the absence of stimulator/cpm in the absence of the stimulator).
